Skip to main content
. 2022 Nov 28;13:1077632. doi: 10.3389/fendo.2022.1077632

Table 1.

Demographic and clinical characteristics of patients with Non-CVD and CVD.

Group Non-CVD (n = 428) CVD (n = 138) Total (n = 566)
Age (years) 47.3 ± 11.7 59.5 ± 10.1 50.3 ± 12.5
Sex (male, %) 260.0 (60.7) 101.0 (73.2) 361.0 (63.8)
BMI(kg/m2) 25.2 (23.2, 27.1) 25.4 (23.4, 27.2) 25.3 (23.2, 27.1)
Smoking, n (%) 152.0 (34.3) 72.0 (52.2) 224.0 (39.6)
Hypertension, n (%) 144.0 (33.6) 80.0 (58.0) 250.0 (44.2)
SBP (mmHg) 135.4 ± 16.7 141.3 ± 19.1 135.0 (125.0, 147.0)
FBG (mmol/L) 9.5 (7.9, 11.7) 9.8 (7.9, 12.4) 9.5 (7.9, 11.9)
PBG (mmol/L) 14.5 (11.7, 17.1) 14.9 ± 4.1 14.6 (11.7, 17.1)
HbA1c (%) 10.8 (9.0, 12.3) 10.6 ± 2.6 10.7 (8.9, 12.4)
FCP (ng/ml) 1.6 (1.1, 2.3) 1.9 (1.3, 2.5) 1.7 (1.2, 2.4)
WBC (10^9g/L) 6.2 (5.4, 7.4) 6.7 (5.7, 8.1) 6.4 (5.5, 7.6)
Hb (g/L) 143.0 (134.0, 152.3) 141.2 (132.0, 149.3) 143 (133, 152)
NLR 1.6 (1.2, 2.0) 1.6 (1.3, 2.1) 1.6 (1.2, 2.0)
FIB (g/L) 2.4 (2.2, 2.9) 2.7 (2.2, 3.0) 2.5 (2.2, 2.9)
D-dimer (ug/L) 130.0 (100.0, 250.0) 160.0 (100.0, 282.5) 140.0 (100.0, 260.0)
ALT (U/L) 25.0 (18.0, 43.0) 27.0 (17.0, 43.0) 26.0 (18.0, 43.0)
AST (U/L) 16.0 (12.0, 23) 15.0 (12.0, 22.0) 16.0 (12.0, 23.0)
ALB (g/L) 37.9 (35.4, 40.2) 36.4 (34.5, 39.2) 37.4 (35.0, 39.9)
Bicarbonate (mmol/L) 23.7 (22.2, 25.6) 24.3 ± 2.7 23.9 (22.2, 25.7)
BUN (mmol/L) 4.7 (3.8, 5.7) 5.5 (4.2, 6.5) 4.8 (3.9, 5.9)
SC r (µmol/L) 69.2 ± 18.2 74.5 ± 16.6 70.5 ± 15.7
UA (µmol/L) 262.8 (211.2, 320.3) 289.5 ± 85.6 269.8 (216.8, 325.6)
CysC (mmol/L) 0.7 (0.6, 0.9) 0.7 (0.6, 0.9) 0.7 (0.6, 0.9)
eGFR (ml/min/1.73 min) 109.5 (91.1, 132.6) 96.1 (79.0, 112.3) 104.8 (88.5, 129.2)
K (mmol/L) 4.3 (4.1, 4.5) 4.2 ± 0.4 4.3 (4.0, 4.5)
Ca (mmol/L) 2.4 (2.3, 2.4) 2.3 (2.3, 2.4) 2.4 (2.3, 2.4)
P (mmol/L) 1.2 (1.1, 1.3) 1.2 ± 0.2 1.2 (1.1, 1.3)
TC (mmol/L) 4.8 (4.1, 5.5) 4.8 (4.3, 5.5) 4.8 (4.2, 5.5)
TG (mmol/L) 2.5 (1.7, 3.7) 2.9 (2.0, 4.2) 2.6 (1.8, 3.8)
HDL (mmol/L) 1.0 (0.9, 1.2) 0.9 (0.8, 1.1) 1.0 (0.9, 1.1)
LDL (mmol/L) 2.3 (1.9, 2.8) 2.4 (2.0, 2.8) 2.3 (1.9, 2.8)
Apoa1 (g/L) 1.2 (1.1, 1.3) 1.2 (1.1, 1.3) 1.2 (1.1, 1.3)
Apob (g/L) 1.0 (0.9, 1.2) 1.1 (0.9, 1.3) 1.0 (0.9, 1.2)
UACR (mg/g) 9.9 (6.7, 16.7) 10.0 (6.7, 18.4) 10.0 (6.7, 16.9)
TyG index 9.8 (9.4, 10.3) 10.1 (9.7, 10.4) 9.9 (9.5, 10.3)
TC/HDL 4.9 (3.9, 5.9) 5.1 (4.3, 6.2) 4.9 (4.0, 5.9)
TSH (uIU/ml) 2.0 (1.3, 2.9) 2.0 (1.3, 2.6) 2.0 (1.3, 2.8)
fT3 (pmol/L) 4.3 (3.9, 4.7) 4.2 ± 0.7 4.3 (3.8, 4.7)
fT4 (pmol/L) 16.6 (15.0, 18.3) 16.5 ± 2.2 16.6 (14.9, 18.3)
QRSKI3 7.5 (3.2, 14.4) 23.8 (16.6, 32.6) 10.6 (4.3, 19.5)
QRSIK3 (<10%), n (%) 262.0 (61.2) 12.0 (8.7) 274.0 (48.4)
QRSIK3 (10%-20%), n (%) 128.0 (29.9) 35.0 (25.4) 163.0 (28.8)
QRSIK3 (> 20%), n (%) 38.0 (8.9) 91.0 (65.9) 129.0 (22.8)
FRS 9.7 (4.7, 18.4) 25.3 (15.6, 30.0) 13.3 (5.6, 21.6)
FRS (<10%), n (%) 214.0 (50.0) 15.0 (10.9) 229.0 (40.5)
FRS (10%-20%), n (%) 129.0 (30.1) 41.0 (29.7) 170.0 (30.0)
FRS (> 20%), n (%) 85.0 (19.9) 82.0 (59.4) 167.0 (29.5)

The eGFR is calculated according to the CKD-EPI formula. CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; PBG, postprandial blood glucose; HbA1c, haemoglobin A1c; FCP, fasting c- peptide; WBC, white blood cell; Hb, haemoglobin; NLR, neutrophil to lymphocyte ratio; FIB, fibrinogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; BUN, blood urea nitrogen; SCr, serum creatinine; UA, uric acid; CysC, cystatin C; eGFR, estimated glomerular filtration rate; TC, total cholesterol; TG, triglycerides; HDL, high density lipoprotein; LDL, low density lipoprotein; Apoa1, apolipoprotein a1; Apob, apolipoprotein b; UACR, urine albumin-to-creatinine ratio; TyG index, triglyceride-glucose index; TSH, thyroid stimulating hormone; fT3, free triiodothyronine; fT4, free thyroxine; QRISK3, QRESEARCH risk estimator version 3; FRS, framingham risk score.